Through my research, I became familiar with three of the approaches being tested to cure AD. The first one being the suppression of the Heme oxygenase-1 (HO-1) protein to cure AD. HO-1 is a 32 kDa stress protein that catalyzes heme to biliverdin, free iron and carbon other tissues in presence of disease and trauma. The HO-1 protein is significantly overexpressed in the temporal cortex and hippocampus of those with AD. In a trial conducted to test the viability of suppressing the HO-1 protein. “Attenuation of neuropathology and behavioural toxicity in the APPswe/PS1 mice by treatment with the HO-1 inhibitor, OB-24 would flag HO-1 as a potential therapeutic target in the management of AD and possibly other aging-related human neurodegenerative diseases” (Schipper 223). Because the trial was only on mice and not humans, the effects on humans is not known and further research needs to be done by scientists to test its viability and become FDA approved.